A Phase II/III Trial of Comparison of Benefit of Administration of Checkpoint Inhibitors Plus Chemodrug Via Artery or Fine Needle to Tumor Versus Vein for Immunotherapy of Advanced Solid Tumors
Latest Information Update: 09 Jul 2024
At a glance
- Drugs Pembrolizumab (Primary) ; Pembrolizumab (Primary) ; Pembrolizumab (Primary) ; Atezolizumab; Ipilimumab
- Indications Solid tumours
- Focus Therapeutic Use
Most Recent Events
- 25 Jun 2024 Planned End Date changed from 1 Nov 2033 to 1 Nov 2036.
- 14 Feb 2020 Planned End Date changed from 1 Nov 2021 to 1 Nov 2033.
- 14 Feb 2020 Planned primary completion date changed from 1 Nov 2020 to 1 Nov 2033.